Similarly, FASLG (log-rank test p = 3.843 × 10−3) and NT5E (log-rank test p = 4.072 × 10−3) expression correlated with lower progression-free survival in the 36 CCA patient cohort (Table 5). The gene discussed is FASLG; the disease is cholangiocarcinoma.